Jonathan Ticku, Assistant Professor of Oncology at Mayo Clinic GU Oncology Lead – Mayo Clinic Health System, shared a post on LinkedIn:
“Community oncology practices face a growing challenge: how to bring bispecific antibody (BsAb) treatments to patients close to home.
While many of these therapies are now FDA-approved, patients often still face major barriers – long travel to referral centers, temporary relocation with a caregiver, hotel stays, and significant financial strain.
That’s why we developed the Mayo Clinic Health System Outpatient Bispecific step-up dosing (SUD) Model – a first-of-its-kind approach designed by community oncologists, for community oncologists.
This hybrid model combines strengths of our well-established Mayo Clinic Rochester approach to bispecific therapy initiation, but with conscientious local deployment in small community outpatient practices across the Midwest.
Our goal is to create a replicable pathway nationwide, so patients can access cutting-edge treatments without leaving their home community. Grateful to my partners in this endeavor, Joshua Pritchett, M.D., and Grant Perschke PharmD, along with our outstanding administrative team. Our approach is leveraging existing technology – such as Remote Patient Monitoring, as pioneered by our colleagues Jonas Paludo M.D and Yi Lin M.D. – and integrating curated educational components, both traditional and new, including an LLM-based chatbot and other modern tools to support patients and providers.
Recently, I had the opportunity to present on this model alongside colleagues Gordon Ruan (HealthPartners), Jennie Goble (Mayo Clinic), Kirollos Hanna, while reviewing published models of outpatient step-up dosing (SUD) – including the Mayo Clinic Referral Campus Model as well as the Emory University Model.”
Joshua Pritchett, Oncologist at Mayo Clinic, shared this post, adding:
“It has been such a privilege to work with my colleague and friend, Jonathan Ticku, M.D., to design this program that will bring access to step-up-dosing for bispecific therapies to patients in our shared community oncology practice. Thanks Jon for your leadership and mentorship!”
You Can Also Read:
